ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Reverse Split

<< Previous

Bullboard Posts

Next >>

Comment by azzymaaon Apr 01, 2022 3:28pm

152 Views

Post# 34568392

RE:Reverse Split

I am only assuming like most Options they will expire worthless and not excercised.
There might not be a Reverse Split and we might not see any Nasdaq Listing.

There are many stipulations in order to get listed on the Nasdaq.

Were the Options at 0.10 for the Boston Club?

Hope someone with more knowledge can reply.

<< Previous

Bullboard Posts

Next >>

The top 10 Canadian medical stocks